Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

26
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
26
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

34
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
34
Portal Hypertension01:22

Portal Hypertension

44
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
44
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

880
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
880
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

380
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in alcohol use following a diagnosis of alcohol-related liver disease: a clinical cohort study.

JHEP reports : innovation in hepatology·2026
Same author

Response to "Methodological and inferential limits before abandoning follow-up in node-negative typical lung carcinoids".

Journal of neuroendocrinology·2026
Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026
Same author

A call for sharing individual patient data from trials in hepatology.

Journal of hepatology·2026
Same author

Effects of Opioids, Benzodiazepines, Gabapentinoids, and Antidepressants on Fracture Risk in Alcohol-Related Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Risk and prognosis of HCC in patients with thyroid disease: A nationwide cohort study.

Hepatology communications·2026
Same journal

Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.

World journal of gastroenterology·2026
Same journal

Small animal <i>ex vivo</i> machine perfusion of the liver: A comprehensive literature review.

World journal of gastroenterology·2026
Same journal

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars.

World journal of gastroenterology·2026
Same journal

Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.

World journal of gastroenterology·2026
Same journal

Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.

World journal of gastroenterology·2026
Same journal

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Comorbidity in cirrhosis.

Peter Jepsen1

  • 1Peter Jepsen, Department of Hepatology and Gastroenterology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.

World Journal of Gastroenterology
|June 27, 2014
PubMed
Summary
This summary is machine-generated.

Comorbidities, or co-existing diseases, significantly impact cirrhosis patient mortality and complicate research. The CirCom score offers a specialized tool for assessing comorbidity burden in cirrhosis.

Keywords:
ComorbidityEpidemiologyLiver cirrhosisPrognosis

More Related Videos

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K

Area of Science:

  • Hepatology
  • Clinical Epidemiology

Background:

  • Comorbidities in cirrhosis patients are distinct from the liver disease itself.
  • These co-existing conditions increase mortality risk and pose challenges in epidemiological studies.
  • Comorbidity scoring systems aid in quantifying the overall disease burden.

Purpose of the Study:

  • To review the existing literature on comorbidities in patients with cirrhosis.
  • To highlight the clinical significance and research implications of comorbidities in cirrhosis.
  • To compare the utility of the CirCom score with traditional comorbidity indices.

Main Methods:

  • Literature review of studies on comorbidity in cirrhosis.
  • Analysis of the role of comorbidities in mortality and confounding.
  • Evaluation of comorbidity scoring systems, including Charlson and CirCom.

Main Results:

  • Comorbidities are independent factors influencing mortality in cirrhosis patients.
  • The CirCom score is a cirrhosis-specific tool, potentially superior to generic indices like Charlson.
  • Individual comorbidity studies offer insights into cirrhosis pathophysiology.

Conclusions:

  • Comorbidities are critical in managing cirrhosis patients and require accurate assessment.
  • Specialized scoring systems like CirCom enhance clinical and research utility.
  • Understanding comorbidity interactions is vital for advancing cirrhosis care and research.